Latest Patents News

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Metal Powder Works has formalized a partnership with Austal USA to develop custom metal powders for US Navy additive manufacturing, positioning MPW within a critical defense supply chain.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

Rhythm Biosciences has begun commercialising ColoSTAT®, its blood-based colorectal cancer diagnostic test, following an updated ISO15189, 2022 accreditation. The test offers a new option for symptomatic patients where stool-based screening is unsuitable.

Temas Resources has engaged a European consultant to elevate its investor awareness across key markets, aiming to strengthen its presence in Germany and broader Europe.

Metal Powder Works Limited has achieved a major production milestone by successfully manufacturing high-purity silver powder using its patented DirectPowder™ process, positioning itself to serve the booming electric vehicle and electronics sectors.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

Way2Vat Limited’s shareholders have overwhelmingly approved a suite of resolutions at the December 2025 Extraordinary General Meeting, including share placements, executive performance options, and a share consolidation.